WEBINAR | Recorded October 1, 2008

Let’s talk about the latest ideas for validating DMEs.

Large linked automated health care databases have been widely used for ad hoc studies to evaluate the safety and effectiveness of medications. In designing and conducting these studies, algorithms that operationally define important clinical outcomes have been proposed, and several of these operational definitions have been validated through review of medical records.

The FDA Sentinel Initiative will lead to more widespread use of large automated data sources for medical product safety surveillance, underscoring the need for a comprehensive list of algorithms to identify important clinical events—such as Designated Medical Events specified by the FDA—as well as the need for a clearer understanding of each algorithm’s positive predictive value regarding the results of safety surveillance conducted using automated databases.

Register today to listen to this informative webinar led by members of i3 Drug Safety’s leadership team. They will discuss:

• i3 Drug Safety's experience in developing algorithms to identify clinical events and the process for evaluating the performance of these algorithms
• Published literature that illustrates the utility of several existing algorithms
• i3 Drug Safety's approach to expanding the knowledge base in this area

www.i3drugsafety.com